My first question is on the domestic side. If you can quantify the contributi on of these in- licensing products to the domestic business?
Okay. And are we still scouting or are we still interested in doing more such in -licensing deals in the near-term?
Thank you for the opportunity. My first question is on margins. Since we expect a spillover effect of the facility shutdown even in the next -- Gagillapur facility shutdown even in the next quarter and we see that the base for the margin base in the -- is higher at 22%. So how much impact do you see of this facility a spillover effect or impact on the margins at an EBITDA level?
Okay, got that. And my second question is on the API side. I see this massive decline both on a Q-o-Q and Y-o-Y basis. So is it because of some price realization, I mean lower price realization or what has led to such massive decline?
My first question is on the India business. So I see that the growth is up 16%. So I just want to understand how sustainable is this 16% growth? Though I understand we would continue to surpass IPM growth, but would it be in this high -- in this mid-teens or can we expect a lower double-digit run rate going forward?
Okay, so 16% growth is of the cardio business?
My first question is, our EBITDA mar gin for H1 has been around 14%, 15%. And with the deleveraging being on the cards for the next couple of quarters, so are we sure we would be able to achieve 20% EBITDA margin for FY '25?
With the deleveraging being on cards...
My first question is, our EBITDA mar gin for H1 has been around 14%, 15%. And with the deleveraging being on the cards for the next couple of quarters, so are we sure we would be able to achieve 20% EBITDA margin for FY '25?
With the deleveraging being on cards...